| CLINICAL TRIAL IN BRISBANE PROVES THAT BUTEYKO WORKS |
| In a clinical trial funded by the Asthma Foundation and held at the Mater Hospital in Brisbane in 1994-1995, two groups of asthmatics were treated under the guidance of a Professor of Medicine a Respiratory Physician, a Physiotherapist and a Buteyko instructor. The 19 patients who underwent the Buteyko training were able to reduce their reliever medication by an average of 96% over a 12 week period. At the same time, they were also able to lower their preventer medication by 49% The control group of 20 patients who were taught standard physiotherapy breathing techniques, showed no more than a 5% reduction in reliever medication and, in some cases, the usage of preventer medication rose by up to 20%. At the end of the trial the 20 patients in the control group were given the Buteyko training and achieved similar results to the original group. |
| BUTEYKO GUIDE FOR DOCTORS |
|
.A brief summary of the practice and theory behind Buteyko. A compulsory read for every doctor who seeks the safest and most effective treatment for the patient. With almost 2000 deaths of asthma sufferers each year in the UK alone, and the continued concern for the safety of asthma drugs (see Buteyko News) by specialists any proven therapy that reduces the reliance on drugs has to be considered seriously and tried. Doctor Gerald Spence, a Glasgow GP, told the QED science programme that Buteyko had had a major impact on his practice. He started the breathing technique after the expensive drug treatments currently on the market appeared to make no difference to his patients. "The simple fact is that 34 patients, prior to Buteyko, were costing £15,000 for their asthma medication," he said. "After Buteyko, they were costing £5,000. That's a reduction of two-thirds in their drugs bill. If this was extended to the rest of the country, very significant savings could be made." (Source: BBC News Online/Health archive) |
| SUMMARY OF BUTEYKO TRIALS |
|
Canada: Cowie RL et al. A Randomised Controlled Trial of the Buteyko technique as an adjunct to conventional management of asthma Respir.Med. (2008) doi:10,1016/j.med 2007 12.012 This study, which we believe to be the largest randomised controlled trial and the first to use a global assessment of asthma control as a primary outcome in a non-pharmacological intervention in asthma, failed to show a difference between the intervention (Buteyko) and control (physiotherapy) groups. These data suggest that both interventions can be considered to have been active with a remarkably high Conclusion This randomised clinical trial showed that both the Buteyko and control (physiotherapy) interventions produced a favourable outcome in that over 70% of the participants enjoyed asthma control 6 months after completing the intervention. In addition, the subjects in the Buteyko group were able to significantly reduce their daily doses of inhaled corticosteroid.
<http://www.buteyko.ru/eng/method.shtml>
United Kingdom:
The science PDF.File Canada 2006: R.L. Cowie, D.P. Conley, M.F. Underwood, P.G. Reader, "A Randomized Controlled Trial of the Buteyko Technique for Asthma Management", American Thoracic Society Abstracts online. http://www.abstracts2view.com/ats06/view.php?nu=ATS06L_1512 The Buteyko technique (BT) was developed to address the hypothesis that asthma is caused by hyperventilation. BT is designed to train people with asthma to breathe less and thus reset their arterial CO2 at a higher level. The study was designed to compare the Buteyko technique with a similarly structured program in which subjects with asthma were trained by a physical therapist (PT) to perform relaxation and other breathing techniques considered routine by PT for asthma.129 subjects with asthma on inhaled corticosteroids were enrolled: 64 were randomized to BT and 65 to the control group. The primary outcome variable was the proportion of subjects whose asthma was controlled 6 months after completion of the program. Secondary outcomes included quality of life (QOL), reduction of the dose of inhaled corticosteroid (ICS) expressed as beclomethasone equivalent and spirometry. No differences in any of the relevant variables were apparent between the two groups on entry. At 6 months, 9 BT and 1 control subject were lost to follow up. The average proportion with disease control had increased from 41% to 75% with no difference between the two groups. Juniper Mini QOL had improved in both groups (+0.95, sd 1.1, p < 0.00001) with no difference between BT and control. The average daily dose of ICS after 6 months was lower in the Buteyko group (548 mcg versus 762 mcg, p = 0.02). 12 BT and 4 control had stopped ICS (p = 0.02). Of the subjects who achieved asthma control, 10 BT and 4 control were no longer using ICS (p = 0.02) No differences were apparent in spirometry between the groups or compared with entry. Conclusion: Both groups displayed substantial improvement in asthma control 6 months after the interventions. The Buteyko group achieved improvement of their asthma status and reduction in ICS. |
| PRACTICAL DRUG-FREE TREATMENT THAT WORKS |
|
The Buteyko method normalises breathing patterns in people who have breathing disorders. In addition to helping asthmatics, it is also of benefit to people suffering from emphysema, acute sinusitis, rhinitis, allergies, sleep apnoea, bronchitis, bronchiectasis and other respiratory problems. Following breathing correction, doctors, dentists, orthodontists and clients have reported some or all of the following: eduction in asthma symptoms and in the need for symptomatic medication unblocking of the nose and sinuses restoration of nasal breathing reduction or elimination of snoring and apnoea reduction in mucus production and allergic rhinitis and sinusitis change in tongue position and occlusion stability to orthodontic work decrease in size of tonsils adenoids & polyps improvement in ability to exercise and enhanced speed, endurance & recovery times Serious dangers using beta-2 agonists, latest research Study suggests Beta_2-agonists increase asthma complicationsJun 09, 2006 - Long-acting beta_2-agonists (LABA) put asthma patients at greater risk of complications compared with placebo, according to results from a large meta-analysisin the USA. The study of 19 controlled trials, including 33,826 patients, showed that those taking a LABA were over 2.5times as likely to be hospitalized and nearly twice as likely to have a life-threatening attack. ÒUse of long-acting beta_2-agonists could be associated with a clinically significant number of unnecessaryhospitalizations, intensive care unit admissions, and deaths each year,Ó claim the authors of the report. See full report below. Summary of trial pdf file Medical insanity reaches new heights Professor Buteyko claimed that modern medicine has been reduced to"blind empiriscm", in other words "trial & error" or "suck it and see" We now know he is right. Research report 27th May 2004 "Antibiotics may raise asthma risk" http://news.bbc.co.uk/1/hi/health/3753465.stm Research report 1st Oct 2003 "Antibiotics link to baby asthma" http://news.bbc.co.uk/1/hi/health/4801118.stm and today Research report13th March 2005 "Antibiotics could treat asthma" http://news.bbc.co.uk/1/hi/health/4899602.stm Where is the philosophy, the science, the sanity? New Zealand National TVÊnews see video below:" Many may have asthma misdiagnosed."Ê 2007 |
Home | Contact | News | About Buteyko | Links
Designed by: AJL Designs